| Literature DB >> 30093175 |
Arifa S Khan1, Luca Benetti2, Johannes Blumel3, Dieter Deforce4, William M Egan5, Ivana Knezevic6, Philip R Krause7, Laurent Mallet8, Dietmar Mayer9, Philip D Minor10, Pieter Neels11, Guanhua Wang12.
Abstract
A fundamental aspect of biological product safety is to assure absence of adventitious agents in the final product. Next-generation or high-throughput sequencing (NGS/HTS) has recently demonstrated detection of viruses that were previously missed using the recommended routine assays for adventitious agent testing of biological products. This meeting was co-organized by the International Alliance for Biological Standardization (IABS) and the U.S. Food and Drug Administration (FDA) to assess the current status and discuss the readiness of NGS for adventitious virus detection in biologics. The presentations included efforts for standardization, case studies on applications in biologics, comparison with routine virus detection assays, and current regulatory thinking. Participants identified the need for standard reference reagents, well-annotated databases, large data storage and transfer capacity, personnel with relevant expertise, particularly in bioinformatics; and harmonization of international regulations for testing biologic products and reagents used for their manufacturing. We hope this meeting summary will be of value to regulators and industry for considerations of NGS applications for adventitious virus detection in biologics.Entities:
Keywords: Adventitious viruses; Bioinformatics; Biologics; Biotherapeutics; Cell substrate; High throughput sequencing; Next generation sequencing; Vaccines
Mesh:
Year: 2018 PMID: 30093175 DOI: 10.1016/j.biologicals.2018.08.002
Source DB: PubMed Journal: Biologicals ISSN: 1045-1056 Impact factor: 1.856